BTIG Research reaffirmed their buy rating on shares of Galapagos (NASDAQ:GLPG) in a research note published on Thursday. They currently have a $118.00 price target on the biotechnology company’s stock.

A number of other equities analysts have also weighed in on the company. ValuEngine raised Galapagos from a sell rating to a hold rating in a research note on Friday, February 2nd. BidaskClub raised Galapagos from a hold rating to a buy rating in a research note on Wednesday, January 31st. Zacks Investment Research lowered Galapagos from a hold rating to a strong sell rating in a research note on Thursday, January 25th. Finally, Stifel Nicolaus reaffirmed a buy rating and issued a $120.00 price target on shares of Galapagos in a research note on Sunday, October 29th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and seven have given a buy rating to the company. Galapagos presently has a consensus rating of Buy and an average target price of $111.00.

Galapagos (NASDAQ:GLPG) opened at $108.83 on Thursday. The firm has a market capitalization of $5,543.47, a price-to-earnings ratio of -118.29 and a beta of 1.85. Galapagos has a 12 month low of $67.26 and a 12 month high of $121.09.

Several institutional investors have recently made changes to their positions in GLPG. Advisors Preferred LLC acquired a new position in shares of Galapagos in the 3rd quarter valued at $105,000. Tower Research Capital LLC TRC lifted its stake in shares of Galapagos by 7,340.0% in the 4th quarter. Tower Research Capital LLC TRC now owns 1,488 shares of the biotechnology company’s stock valued at $140,000 after purchasing an additional 1,468 shares during the last quarter. New York State Common Retirement Fund acquired a new position in shares of Galapagos in the 2nd quarter valued at $166,000. Envestnet Asset Management Inc. lifted its stake in shares of Galapagos by 156.6% in the 3rd quarter. Envestnet Asset Management Inc. now owns 1,742 shares of the biotechnology company’s stock valued at $177,000 after purchasing an additional 1,063 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership acquired a new position in shares of Galapagos in the 2nd quarter valued at $214,000. 19.71% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: This report was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this report on another publication, it was copied illegally and reposted in violation of U.S. & international copyright and trademark laws. The legal version of this report can be read at https://www.thecerbatgem.com/2018/02/12/btig-research-reaffirms-buy-rating-for-galapagos-glpg.html.

About Galapagos

Galapagos NV is a Belgium-based biotechnology company. The Company’s activities are divided into two operating divisions: Research and Development (R & D) and Services. The R & D division is engaged in the discovery and development of small molecules. The Services division, offers target-to-drug discovery products and services to pharmaceutical and biotechnology companies and to patient foundations, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates.

Analyst Recommendations for Galapagos (NASDAQ:GLPG)

Receive News & Ratings for Galapagos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galapagos and related companies with MarketBeat.com's FREE daily email newsletter.